01 / Diagnose
Find the cause
Identifies denial patterns and likely root causes, reducing manual claim-by-claim investigation.
Private investment opportunity
Red Sky Health SPV
Red Sky Health is building Daniel, an AI-powered insurance denial-remediation platform designed to identify fixable errors, recommend corrective actions, and help healthcare providers recover revenue that might otherwise remain uncollected.
SPV target$600K targeted raise & deployment
Company round$2M seed round
Reported availability$500K remaining
Business modelOutcome-based recovery fee
Participation is subject to investor eligibility, strategic fit, available allocation, independent diligence, and completion of definitive offering documentation.
The investment case
A measurable healthcare revenue problem
Insurance denials create a persistent cash-flow and operating burden for providers. Red Sky combines denial diagnosis, payer-specific recommendations, tracking, and recovery operations in one workflow, with fees aligned to dollars recovered.
$5T+U.S. claims submitted annually
16%Initially denied, company estimate
86%Denials attributed to fixable errors
66–75%Denied claims reportedly never resubmitted
The platform
Daniel turns denials into a recovery workflow
Daniel is positioned as a virtual denial-remediation analyst. It combines claim and denial data with payer rules, prior outcomes, and AI-driven recommendations. A planned API strategy could extend the capability into billing platforms, clearinghouses, RCM vendors, and specialty software.
02 / Recommend
Define the correction
Suggests payer-specific corrections to improve consistency and recovery readiness.
03 / Recover
Move claims forward
Tracks and programmatically resubmits eligible claims to accelerate recovered cash and reduce leakage.
04 / Learn
Build payer intelligence
Uses historical outcomes to improve payer intelligence and create a data advantage as activity scales.
Economic evidence
A modeled recovery opportunity
Red Sky analyzed a 2024 population of 820,468 unique claim lines. The comparison is a retrospective company model, not prospective clinical or commercial validation.
Modeled recovery
The company model indicates approximately $8.4 million in additional recovery versus the historical baseline, or roughly 4.1 times total recovered revenue, subject to implementation, claim eligibility, payer behavior, and prospective validation.
Because Red Sky earns a portion of recovered revenue, provider cost is directly connected to measurable collections.
Historical vs. modeled
| Measure | Baseline | Modeled |
|---|---|---|
| Claims resubmitted | 49K | ~198K |
| Claims later paid | 25K | ~101K |
| Recovered revenue | $2.7M | $11.1M |
| Resubmission success | 50.82% | 51.19% |
Commercial path
From practices to health systems
Company materials report product and model validation with small medical groups in 2025, followed by scaling efforts into larger practices and health systems during 2026.
Reported proof points
Red Sky identifies five practices representing an estimated revenue opportunity of approximately $50,000 per month each.
The company also describes a pilot with University Hospitals in Ohio, estimating roughly 80,000 outpatient denials per month and more than $100,000 per month of potential Red Sky revenue.
Contract status, go-live timing, retention, realized collections, and pilot results should be confirmed in diligence. These are opportunity figures, not recognized revenue.
Expansion strategy
- Direct enterprise sales supported by performance marketing, content, events, and experienced advisors.
- Channel partnerships with medical billing firms, RCM providers, clearinghouses, and specialty healthcare software.
- An API-led embedding model that places recovery intelligence inside existing workflows.
- Longer-term payer intelligence and new products based on accumulated denial and recovery outcomes.
Leadership
Operating and technical experience
The team combines startup leadership, healthcare operations, enterprise sales, revenue-cycle experience, and AI product development.
Startup veteran with experience including LivePerson and Reonomy, spanning company formation through acquisition and public-market outcomes.
Healthcare operator with medical-practice, billing, revenue-cycle, and denial-management experience.
Enterprise technology sales leader with experience at Microsoft, Cisco, and EMC, plus performance marketing for health-insurance carriers.
Leadership includes CTO Jon Jaroska, CPO Joe Melito, SVP Business Development Ted Pantaleo, and AI, software, and data-science contributors.
Investment lens
Potential strengths and diligence priorities
The remaining seed proceeds are intended to fund customer acquisition and support, continued AI platform development, and a bridge to a potential Series A in early 2027.
Potential strengths
- Large, measurable revenue-leakage problem.
- Outcome-aligned commercial model.
- Workflow product with embedded API potential.
- Early path from practices to health systems.
- Potential data flywheel from denial and recovery outcomes.
Priority diligence questions
- What recovery lift has been demonstrated prospectively by cohort?
- Which customers are contracted, live, and paying today?
- How are PHI, security, auditability, and model risk managed?
- What integrations and human review remain necessary at scale?
- What are gross margin, implementation time, and revenue concentration?
A limited strategic allocation
Red Sky is prioritizing strategic capital
The company expects a final group of approximately 15 to 25 individuals who can contribute relevant operating judgment, customer access, industry relationships, or follow-on support. Participation remains subject to strategic fit and available allocation.
Apply to investSource and diligence note
This page is based on Red Sky Health materials dated August 2026, including the executive summary, investor deck, investment memo, and founder video. Market, customer, pilot, revenue-opportunity, and modeled-recovery figures are company-provided and have not been independently verified. This page is for discussion purposes only and is not an offer to sell or a solicitation to purchase securities. Any investment should be made only through definitive offering materials and after independent diligence.